News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
73–94
Matches
94
Sources here
18
Companies here
7
Search results Stored financial headlines

Active search

94 matching headlines

Ticker or company: ENWMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Is Genworth Financial (GNW) Stock Undervalued Right Now?

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong …

GNW main company
Sharemaestro market context Trend signal active 52 weeks +17.1% GNW stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Greenwich trial opens enrollment to patients representing about 55% of population

Greenwich LifeSciences (GLSI) provided clinical updates for its Phase III FLAMINGO-01 breast cancer trial, which evaluates GLSI-100. The trial design has been expanded to include non-HLA-A*02 patients, representing about 55% of the population, which is expected to increase enrollment by 122% and accelerate the …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

Greenwich LifeSciences (GLSI) provided clinical updates for its Phase III FLAMINGO-01 trial, reporting that its Data Safety Monitoring Board recommended continuing the study without modification. The company announced regulatory approval from the FDA and EMA for previously planned modifications to increase study size, enrollment …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

The Technical Signals Behind (GLSI) That Institutions Follow

This article analyzes the technical signals for Greenwich Lifesciences Inc. (GLSI) that institutions monitor. It highlights divergent sentiment, indicating choppy conditions and an ongoing breakdown with elevated downside risk. The report provides AI-generated trading strategies (position, momentum, and risk hedging) and a multi-timeframe signal …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Greenwich LifeSciences Becomes Oversold (GLSI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Greenwich unifies 180-site FLAMINGO-01 trial protocol

Greenwich LifeSciences (NASDAQ:GLSI) announced that European regulators approved combining HLA-A 02 and non-HLA-A 02 patients in the randomized arms of its FLAMINGO-01 trial. This unification, already adopted by U.S. sites, is expected to accelerate enrollment and supports a potential approval pathway for both HLA …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Greenwich LifeSciences Announces European Approval For Combining Both HLA Populations In FLAMINGO-01

Greenwich LifeSciences has received European Medicines Agency (EMA) approval to combine both HLA-A*02 and non-HLA-A*02 patient populations in its FLAMINGO-01 clinical trial, mirroring a prior FDA approval. This change standardizes the protocol across US and European sites, potentially doubling the market for GP2 and …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Greenwich LifeSciences expands trial enrollment in Europe By Investing.com

Greenwich LifeSciences (NASDAQ:GLSI) has announced that the European Medicines Agency approved the inclusion of both HLA-A02 and non-HLA-A02 patients in its FLAMINGO-01 Phase III clinical trial, aligning European and U.S. protocols. The company, which is evaluating GLSI-100 to prevent breast cancer recurrences, reported a …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

A breast cancer trial can now enroll patients who waited up to a year

Greenwich LifeSciences (Nasdaq: GLSI) announced that the European Medicines Agency (EMA) has approved combining both HLA-A*02 and non-HLA-A*02 patients in the randomized arms of its Phase III FLAMINGO-01 trial for GLSI-100, which aims to prevent breast cancer recurrences. This decision unifies the protocol across …

GLSI main company
Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup negative 44.2% GLSI stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context